About: COVID-19, hypertension and cardiovascular diseases: Should we change the therapy?

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: COVID-19, hypertension and cardiovascular diseases: Should we change the therapy? Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	COVID-19, hypertension and cardiovascular diseases: Should we change the therapy?
Creator	Com, Marijana_Tadic@hotmail Cuspidi, Cesare Cuspidi, Dell'oro, Raffaella Grassi, Grassi, Guido Mancia, Giuseppe Mancia, Marijana Tadic, Assoc Tadic, Marijana
source	Elsevier; Medline; PMC
abstract	The coronavirus disease (COVID-19) has spread all around the world in a very short period of time. Recent data are showing significant prevalence of arterial hypertension and cardiovascular diseases (CVD) among patients with COVID-19, which raised many questions about higher susceptibility of patients with these comorbidities to the novel coronavirus, as well as the role of hypertension and CVD in progression and the prognosis of COVID-19 patients. There is a very limited amount of data, usually obtained from a small population, regarding the effect of the underlying disease on the outcome in patients with COVID-19. The evaluation of the treatment of these comorbidities at baseline and during COVID-19 is scarce and the results are conflicting. Hypertension and CVD, after the adjustment for other clinical and demographic parameters, primarily age, did not remain independent predictors of the lethal outcome in COVID-19 patients. Some investigations speculated about the association between the renin-angiotensin-aldosterone system (RAAS) and susceptibility to COVID-19, as well as the relationship between RAAS inhibitors and the adverse outcome in these patients. Withdrawing or switching RAAS inhibitors would have uncertain benefits, but it would definitely have many disadvantages such as uncontrolled hypertension, cardiac function deterioration and renal function impairment, which could potentially induce more complications in patients with COVID-19 than the infection of coronavirus itself. The aim of this review article was to summarize the prevalence of hypertension and CVD in patients with COVID-19, their influence on the outcome and the effect of treatment of hypertension and CVD in COVID-19 patients.
has issue date	2020-05-13(xsd:dateTime)
bibo:doi	10.1016/j.phrs.2020.104906
bibo:pmid	32405229
has license	no-cc
sha1sum (hex)	f366229ee963f4e585acb6512f7c2e9286412696
schema:url	https://doi.org/10.1016/j.phrs.2020.104906
resource representing a document's title	COVID-19, hypertension and cardiovascular diseases: Should we change the therapy?
has PubMed Central identifier	PMC7217779
has PubMed identifier	32405229
schema:publication	Pharmacol Res
resource representing a document's body	covid:f366229ee963f4e585acb6512f7c2e9286412696#body_text
is schema:about of	named entity 'uncontrolled' named entity 'remain' named entity 'disease' named entity 'switching' named entity 'CVD' named entity 'patients' named entity 'population' named entity 'COVID-19' named entity 'cardiac' named entity 'inhibitors' named entity 'COVID-19' named entity 'data' named entity 'lethal' named entity 'cardiovascular diseases' named entity 'data' named entity 'higher' named entity 'coronavirus' named entity 'comorbidities' named entity 'renal function' named entity 'progression' named entity 'independent' named entity 'prevalence' named entity 'hypertension' named entity 'Journal' named entity 'COVID-19' named entity 'infection' named entity 'hypertension' named entity 'RAAS' named entity 'Hypertension' named entity 'hypertension' named entity 'COVID-19' named entity 'COVID-19' named entity 'prognosis' named entity 'SARS-CoV' named entity 'ACE2' named entity 'ACEI' named entity 'COPD' named entity 'social media' named entity 'pulmonary hypertension' named entity 'COVID' named entity 'SARS-CoV-2' named entity 'membrane-bound' named entity 'ACE2' named entity 'ACE2' named entity 'North America' named entity 'RAAS' named entity 'hypertension' named entity 'mRNA' named entity 'mortality rate' named entity 'intensive care unit' named entity 'SARS-CoV-2' named entity 'RAAS' named entity 'ACEI' named entity 'COVID' named entity 'COVID-19' named entity 'ARBs' named entity 'hypertension' named entity 'cardiac tissue' named entity 'RAAS' named entity 'ARBs' named entity 'SARS-CoV-2' named entity 'hypertensive' named entity 'angiotensin II receptor blockers' named entity 'kidney' named entity 'COVID-19' named entity 'SARS' named entity 'ACE2' named entity 'COVID' named entity 'coronary heart disease' named entity 'ACE2' named entity 'COVID' named entity 'ACEIs'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software